Oct 31, 2024
Roche’s bispecific antibody, trontinemab, demonstrates significant potential in Alzheimer’s treatment, rapidly reducing amyloid plaques in early-stage trials, despite a reported patient death. (Source)
Oct 30, 2024
The National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Pfizer’s bispecific T-cell engager, Elrixfio, as a treatment for multiple myeloma. (Source)
Oct 29, 2024
GSK Invests $300 Million in Chimagen’s Phase 1 Bispecific Antibody, CMG1A46, Targeting Lupus. (Source)
Crescent Biopharma merges with GlycoMimetics, raising $200M for bispecific antibody cancer therapy. (Source)
Oct 16, 2024
Akeso Biopharma’s Cadonilimab demonstrated positive progression-free survival (PFS) and overall survival (OS) in a Phase 3 study for first-line treatment of cervical cancer. (Source) Cadonilimab is a bispecific antibody that targets the PD-1 and CTLA-4 receptors on tumor cells to treat various solid cancers.
Oct 13, 2024
Akeso Biopharma receives $250 million investment to fuel global growth of its innovative drug pipeline. (Source)
Oct 02, 2024
AstraZeneca and Arcus collaborate on clinical trial to evaluate casdatifan and volrustomig for renal cell carcinoma. (Source)
ABL Bio, announced a partnership with MSD (Merck & Co.) to evaluate its experimental drug, ABL103 (bispecific antibody), in combination with KEYTRUDA® (pembrolizumab), an immunotherapy treatment, for patients with advanced cancers. (Source)
Oct 01, 2024
Biohaven Pharmaceuticals has successfully priced a $250 million public offering of common stock. Bispecific antibody, small molecule, inflammation, cancer (Source)
Sept 29, 2024
JMT-Bio Technology, a CSPC Pharmaceutical Group subsidiary, in-licenses exclusive China rights to bispecific ADC JSKN003 from Jiangsu Alphamab Biopharmaceuticals (Alphamab Oncology subsidiary) for up to RMB 3.08 billion ($438 million). (Source)
Sept 27, 2024
Johnson & Johnson announced that a novel combination of TALVEY® and TECVAYLI® demonstrated promising results in treating relapsed or refractory multiple myeloma, with high response rates and sustained remission in patients resistant to all three major classes of treatment, including those with extramedullary disease. (Source)
Sept 25, 2024
OncoC4 and AcroImmune‘s merger brings together AI-081, a promising PD-1/VEGF bispecific antibody, and the clinical-stage AI-071. (Source)
Sept 23, 2024
Eradivir raises $10.25M in Series A funding to complete Phase 2a study of influenza therapeutic. (Source)
